Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion

Blood

Volumn 87, Issue 10, 1996, Pages 4235-4244

  Tsai, Han Mou ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; CALCIUM ION; EDETIC ACID; EGTAZIC ACID; GUANIDINE; METALLOPROTEINASE; PLASMIN; PROTEINASE; VON WILLEBRAND FACTOR;

ARTICLE; CONCENTRATION RESPONSE; ENZYME ASSAY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME DEGRADATION; ENZYME PURIFICATION; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; SHEAR STRESS; VON WILLEBRAND DISEASE;

EID: 0029878123     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4235.bloodjournal87104235     Document Type: Article

References (34)

1. Fuster V, Badimon L, Badimon J-J, Ip JH, Chesebro JH: The porcine model for the understanding of thrombogenesis and atherosclerosis. Mayo Clin Proc 66:818, 1991
2. Badimon L, Badimon JJ, Chesebro JH, Fuster V: von Willebrand factor and cardiovascular disease. Thromb Haemost 70:111, 1993
3. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332:635, 1995
4. Jansson JH, Nilsson TK, Johnson O: von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death. Br Heart J 66:351, 1991
5. Wick TM, Moake JL, Udden MM, Eskin SG, Sears DA, McIntire LV: Unusually large von Willebrand factor multimers increase adhesion of sickle erytnrocytes to human endothelial cells under controlled flow. J Clin Invest 80:905, 1987
6. Kaul DK, Nagel RL, Chen D, Tsai HM: Sickle erythrocyte-endothelial interaction in microcirculation: The role of von Willebrand factor and implications for vasoocclusion. Blood 81:2429, 1993
7. Tsai HM, Nagel RL, Hatcher VB, Sussman II: Multimeric composition of endothelial cell-derived von Willebrand factor. Blood 73:2074, 1989
8. Tsai HM, Nagel RL, Hatcher VB, Seaton AC, Sussman II: The high molecular weight form of endothelial cell von Willebrand factor is released by the regulated pathway. Br J Haematol 79:239, 1991
9. Handin RI, Wagner DD: Molecular and cellular biology of von Willebrand factor. Prog Hemostas Thromb 9:233, 1989
10. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH: Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (type IIC, IID, and IIE). J Clin Invest 77:947, 1986
11. Tsai HM, Nagel RL, Sussman II: Subunit composition of plasma von Willebrand factor multimers: Evidence for a non-proteolytic mechanism resulting in apparent increase in proteolytic fragments. Thromb Res 63:179, 1991
12. Dent JA, Galbusera M, Ruggeri ZM: Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 88:774, 1991
13. Tsai HM, Nagel RL, Hatcher VB Sussman II: Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun 158:980, 1989
14. Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA: Substructure of human von Willebrand factor. J Clin Invest 76:1491, 1985
15. Phillips MD, Vu C, Nolasco L, Moake JL: Granulocyte proteases do not process endothelial cell-derived unusually large von Willebrand factor multimers to plasma vWF in vivo. Am J Hematol 37:80, 1991
16. Tsai HM, Sussman II, Nagel RL: Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 83:2171, 1994
17. Zucker MB, Kim S-J, McPherson J, Grant RA: Binding of factor VIII to platelets in the presence of ristocetin. Br J Haematol 35:535, 1977
18. Tsou C-L: Conformational flexibility of enzyme active sites. Science 262:380, 1993
19. Ruggeri ZM, Ware J: von Willebrand factor. FASEB J 7:308, 1993
20. Ohmori K, Fretto LJ, Harrison RL, Sw EP, Erickson HP, McKee PA: Electron microscopy of human factor VIII/von Willebrand glycoprotein: Effect of reducing reagents on structure and function. J Cell Biol 95:632, 1982
21. Loscalzo J, Handin RI: Conformational domains and structural transitions of human von Willebrand protein. Biochemistry 23:3880, 1984
22. Berkowitz SD, Dent JD, Roberts J, Fujimura Y, Plow EF, Titani K, Ruggeri ZM, Zimmerman TS: Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type UA von Willebrand disease from those generated by plasmin. J Clin Invest 79:524, 1987
23. Zucker S, Lysik RM, Zarrabi HM, Moll U, Tickle SP, Stetler-Stevenson W, Baker T, Docherty AJP: Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexs in cancer. Ann NY Acad Sci 732:248, 1994
24. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726, 1994
25. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM: Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 87:6306, 1990
26. Frangos JA, Moake JL, Nolasco L, Phillips MD, McIntire LV: Cryosupernatant regulates accumulation of unusually large vWF multimers from endothelial cells. Am J Physiol 256:H1635, 1989
27. Phillips MD, Moake JL, Nolasco L, Garcia R: Plasma von Willebrand factor processing activity functions like a disulfide bond reduclase: Reversible decrease of multimer size. Thromb Haemost 69:1199a, 1993
28. Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B: Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 90:7503, 1993
29. Levene RB, Booyse FM, Chediak J, Zimmerman TS, Livingston DM, Lynch DC: Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA won Willebrand disease. Proc Natl Acad Sci USA 84:6550, 1987
30. Ginsburg D, Bowie EJW: Molecular genetics of von Willebrand disease. Blood 79:2507, 1992
31. Moake JL, McPherson PD: Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 87:9N, 1989
32. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR: Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 67:758, 1986
33. Weinstein M, Ware JA, Troll J, Salzman E: Changes in von Willebrand factor during cardiac surgery: Effect of desmopressin acetate. Blood 71:1648, 1988
34. Federici AB, Berkowitz SD, Lattuada A, Mannucci PM: Degradation of von Willebrand factor in patients with acquired clinical conditons in which there is heightened proteolysis. Blood 81:720, 1993